Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15057MR)

This product GTTS-WQ15057MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15057MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9298MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ8739MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ10619MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ4189MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ13955MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ77MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5866MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW